Abstract:Glioblastoma is the most common histologic type of all gliomas and contributes to 57.3% of all cases. Despite the standard management based on surgical resection and radiotherapy, it is related to poor outcome, with a 5-year relative survival rate below 6.9%. In order to improve the overall outcome for patients, the new therapeutic strategies are needed. Herein, we describe the current state of knowledge on novel targeted therapies in glioblastoma. Based on recent studies, we compared treatment efficacy measured by overall survival and progression-free survival in patients treated with selected potential antitumor drugs. The results of the application of the analyzed inhibitors are highly variable despite the encouraging conclusions of previous preclinical studies. This paper focused on drugs that target major glioblastoma kinases. As far, the results of some BRAF inhibitors are favorable. Vemurafenib demonstrated a long-term efficacy in clinical trials while the combination of dabrafenib and trametinib improves PFS compared with both vemurafenib and dabrafenib alone. There is no evidence that any MEK inhibitor is effective in monotherapy. According to the current state of knowledge, BRAF and MEK inhibition are more advantageous than BRAF inhibitor monotherapy. Moreover, mTOR inhibitors (especially paxalisib) may be considered a particularly important group. Everolimus demonstrated a partial response in a significant proportion of patients when combined with bevacizumab, however its actual role in the treatment is unclear. Neither nintedanib nor pemigatinib were efficient in treatment of GBM. Among the anti-VEGF drugs, bevacizumab monotherapy was a well-tolerated option, significantly associated with anti-GBM activity in patients with recurrent GBM. The efficacy of aflibercept and pazopanib in monotherapy has not been demonstrated. Apatinib has been proven to be effective and tolerable by a single clinical trial, but more research is needed. Lenvatinib is under trial. Finally, promising results from a study with regorafenib may be confirmed by the ongoing randomized AGILE trial. The studies conducted so far have provided a relatively wide range of drugs, which are at least well tolerated and demonstrated some efficacy in the randomized clinical trials. The comprehensive understanding of the molecular biology of gliomas promises to further improve the treatment outcomes of patients.

Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma

Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

The Advances in Targeted Therapy and Immunotherapy for Glioblastoma: Basic Research and Clinical Trials

The Potential for Targeting AVIL and Other Actin-Binding Proteins in Rhabdomyosarcoma

Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration

Adeno‐associated virus (AAV)-based gene therapy for glioblastoma

New Directions in the Therapy of Glioblastoma

Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells

Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions

Advances in Chemokine Signaling Pathways as Therapeutic Targets in Glioblastoma

Challenges and Promise for Glioblastoma Treatment through Extracellular Vesicle Inquiry

Glioblastoma precision therapy: From the bench to the clinic.

Emerging therapies for glioblastoma: current state and future directions

Efficacy and Safety of Bevacizumab for the Treatment of Glioblastoma.

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme

Targeting Innate Immunity in Glioma Therapy

New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme

Ivacaftor Inhibits Glioblastoma Stem Cell Maintenance and Tumor Progression

Modulation of blood-tumor barrier transcriptional programs improves intra-tumoral drug delivery and potentiates chemotherapy in GBM

A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007

Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives